3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Ovarian Neoplasms
24
Fallopian Tube Neoplasms
20
Breast Neoplasms
10
Carcinoma, Ovarian Epithelial
8
Sarcoma
6
Neoplasms
4
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Sarcoma, Kaposi
2
Sarcoma, Ewing
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Multi-centric Castleman's Disease
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell
2
Leiomyosarcoma
2
Hodgkin Disease
2
Burkitt Lymphoma
2
Acquired Immunodeficiency Syndrome
2
AIDS-related Kaposi sarcoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Vaccinia
1
Uterine Cervical Neoplasms
1
Sarcoma, Synovial
1
Rhabdomyosarcoma
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma
1
Recurrence
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Interventions
Rituximab
52
Cyclophosphamide
49
Lenalidomide
40
fludarabine
24
obinutuzumab
22
Prednisone
18
Magnetic Resonance Spectroscopy
18
Bendamustine Hydrochloride
18
Vincristine
16
fludarabine phosphate
15
Specimen Handling
15
Doxorubicin
15
zanubrutinib
13
Biopsy
12
tazemetostat
10
ibrutinib
10
Whole-Body Irradiation
10
pembrolizumab
9
Peripheral Blood Stem Cell Transplantation
9
venetoclax
8
Mycophenolic Acid
7
Etoposide
7
axicabtagene ciloleucel
6
Radiotherapy
6
CT-P10
6
Therapeutics
5
R-CHOP protocol
5
tisagenlecleucel
4
tafasitamab
4
polatuzumab vedotin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
liposomal doxorubicin
×
1 year
×
Clear all
NCT06425302
2026-01-08
GOLSEEK-2
Celgene
Phase 2
Active not recruiting
90 enrolled